Literature DB >> 10622214

Antinociceptive effect and enzymatic degradation of endomorphin-1 in newborn rat spinal cord.

A Sugimoto-Watanabe1, K Kubota, K Fujibayashi, K Saito.   

Abstract

Recently discovered endomorphin-1 and -2 are the first endogenous agonists selective for the mu-opioid receptor. We examined the antinociceptive effect and enzymatic degradation of endomorphin-1 in the newborn rat spinal cord. Endomorphin-1 inhibited the binding of [3H][D-Ala2, N-Me-Phe4, Gly-ol5] enkephalin (DAMGO) to the membrane fraction of the newborn rat spinal cord as potently as DAMGO and morphine. Endomorphin-1 at 1-1,000 nM reduced the slow ventral root potential, which reflects noxious transmission in the isolated newborn rat spinal cord, concentration-dependently via the mu-opioid receptor. A similar effect was observed with endomorphin-2. The newborn rat spinal cord homogenate degraded endomorphin-1 in a 120-min incubation procedure, while it degraded [Leu5]enkephalin even in a 30-min incubation procedure. The degradation of endomorphin-1 was inhibited by actinonin but not by thiorphan. These results showed that in the newborn rat spinal cord, endomorphins had high affinity for the mu-opioid receptor and exerted mu-opioid-receptor-mediated inhibitory effects on noxious responses. Endomorphin-1 was degraded by peptidases, but slowly compared with [Leu5]enkephalin degradation, and the degrading enzymes were actinonin-sensitive peptidases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10622214     DOI: 10.1254/jjp.81.264

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  2 in total

1.  Kinetic studies of novel inhibitors of endomorphin degrading enzymes.

Authors:  Renata Perlikowska; Jakub Fichna; Jean Claude do-Rego; Katarzyna Gach; Anna Janecka
Journal:  Med Chem Res       Date:  2011-05-20       Impact factor: 1.965

2.  An Engineered Endomorphin-2 Gene for Morphine Withdrawal Syndrome.

Authors:  Fei-Xiang Wu; Yan He; Hui-Ting Di; Yu-Ming Sun; Rui-Rui Pan; Wei-Feng Yu; Renyu Liu
Journal:  PLoS One       Date:  2016-03-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.